Skip to main content
SpringerLink
Log in

Microwave Ablation Combined with Cellular Immunotherapy for Hepatocellular Carcinoma

  • Chapter
  • First Online:
Microwave Ablation Treatment of Solid Tumors

  • 1214 Accesses

Abstract

Hepatocellular carcinoma (HCC) is the most common liver malignancy with a rising incidence. The treatment options for HCC are limited and disappointing mainly due to the high recurrence rate even after radical treatment. The immune system plays a pivotal role in the development of HCC. It usually can protect against the HCC occurrence and development to some extent, as well as against recurrence after surgical resection or thermal ablation treatment. Therefore, many strategies are employed to modulate HCC patients’ immune system for improvement of clinical outcome. Immunotherapy is a relatively new approach for tumor therapy. The aim of immunotherapy is to enhance the natural antitumor immunity of HCC patients, to act against hepatitis or destroy malignantly transformed cells, and to break the immunosuppressive barriers established by HCC. For the management of HCC, thermal ablation techniques including microwave ablation, radiofrequency ablation, and high-intensity focused ultrasound have become increasingly popular. In this chapter, a systematic review is presented, which mainly emphasizes on the efficacy of microwave ablation, combined with immunotherapy for HCC management, including the relationship between the immune system and HCC occurrence, as well as immunoreaction following thermal ablation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CEA:

Carcinoembryonic antigen

CIK:

Cytokine-induced killer

CTL:

Cytotoxic T lymphocyte

DC:

Dendritic cell

HCC:

Hepatocellular carcinoma

HSP:

Heat shock protein

MWA:

Microwave ablation

NK:

Natural killer cells

RFA:

Radiofrequency ablation

RFS:

Recurrence-free survival

SEC:

Staphylococcal enterotoxin C

TACE:

Transcatheter arterial chemoembolization

References

  1. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol. 2010;10:830–4.

    Google Scholar 

  2. Couzin-Frankel J. Immune therapy steps up the attack. Science. 2010;330:440–3.

    Article  CAS  PubMed  Google Scholar 

  3. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155:1795–801.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ, Chen Y. Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol. 2009;34:829–36.

    CAS  PubMed  Google Scholar 

  5. Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol. 2010;134:237–50.

    Article  CAS  PubMed  Google Scholar 

  6. Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben- Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci. 2010;107:2207–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998;188:341–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  PubMed  Google Scholar 

  9. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009;16:295–308.

    Article  CAS  PubMed  Google Scholar 

  10. Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg. 2012;397:673–80.

    Article  PubMed  Google Scholar 

  11. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45:246–53.

    Article  CAS  PubMed  Google Scholar 

  12. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–93.

    Article  PubMed  Google Scholar 

  13. Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451–8.

    Article  CAS  PubMed  Google Scholar 

  14. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer. 2003;106:81–9.

    Article  CAS  PubMed  Google Scholar 

  16. Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16(30):1–18.

    Article  Google Scholar 

  17. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48.

    Article  CAS  PubMed  Google Scholar 

  18. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology. 1999;30:413–21.

    Article  CAS  PubMed  Google Scholar 

  19. Nagao M, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Ko S, Tatekawa Y, Ikeda N, Kanokogi H, Urizono Y, Kobayashi T, Shibaji T, Kanamura T, Ogawa S, Nakano H. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology. 2000;32:491–500.

    Article  CAS  PubMed  Google Scholar 

  20. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682–90.

    Article  CAS  PubMed  Google Scholar 

  21. Hsu PN, Yang TC, Kao JT, Cheng KS, Lee YJ, Wang YM, Hsieh CT, Lin CW, Wu YY. Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma. Liver Int. 2010;30:1379–86.

    Article  CAS  PubMed  Google Scholar 

  22. Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y. Decreased expression of CD28 coincides with the downmodulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J Gastroenterol Hepatol. 2004;19:1348–56.

    Article  CAS  PubMed  Google Scholar 

  23. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128:887–96.

    Article  CAS  PubMed  Google Scholar 

  24. Evans SS, Wang WC, Bain MD, Burd R, Ostberg JR, Repasky EA. Fever-range hyperthermia dynamically regulates lymphocyte delivery to high endothelial venules. Blood. 2001;97:2727–33.

    Article  CAS  PubMed  Google Scholar 

  25. Xu Y, Choi J, Hylander B, Sen A, Evans SS, Kraybill WG, Repasky EA. Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin. Int J Hyperthermia. 2007;23:513–27.

    Article  CAS  PubMed  Google Scholar 

  26. Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol. 2006;177:7849–57.

    Article  CAS  PubMed  Google Scholar 

  27. Mambula SS, Calderwood SK. Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia. 2006;22:575–85.

    Article  CAS  PubMed  Google Scholar 

  28. Boya P, González-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005;25:1025–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002;277:6504–10.

    Article  CAS  PubMed  Google Scholar 

  30. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3–12.

    Article  CAS  PubMed  Google Scholar 

  31. Ghanamah M, Berber E, Siperstein A. Pattern of carcinoembryonic antigen drop after laparoscopic radiofrequency ablation of liver metastasis from colorectal carcinoma. Cancer. 2006;107:149–53.

    Article  PubMed  Google Scholar 

  32. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95:896–905.

    Article  Google Scholar 

  33. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C, Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66:1139–46.

    Article  CAS  PubMed  Google Scholar 

  34. Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138:1931–42.

    Article  CAS  PubMed  Google Scholar 

  35. Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006;12:3716–21.

    PubMed Central  PubMed  Google Scholar 

  36. Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, Rahimi H, Pauselli S, Pellicciotta I, Burchell JM, Gaspari LA, Ercoli L, Rossi P, Rughetti A. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008;32:481–90.

    PubMed  Google Scholar 

  37. Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanović S, Pereira PL, Rammensee HG, Gouttefangeas C. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 2011;128:2653–62.

    Article  CAS  PubMed  Google Scholar 

  38. Rao P, Escudier B, de Baere T. Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis. Cardiovasc Intervent Radiol. 2011;34:424–30.

    Article  PubMed  Google Scholar 

  39. Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg. 2005;29:1364–73.

    Article  PubMed  Google Scholar 

  40. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113:1515–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401–11.

    Article  CAS  PubMed  Google Scholar 

  42. Zhou P, Liang P, Dong B, Yu X, Han X, Wang Y, Han Z. Long-term results of a phase II clinical trial of superantigen therapy with staphylococcal enterotoxin C after microwave ablation in hepatocellular carcinoma. Int J Hyperthermia. 2011;27:132–9.

    Article  PubMed  Google Scholar 

  43. Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014;134:342–51.

    Article  PubMed  Google Scholar 

  44. Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother. 2013;36:287–93.

    Article  PubMed  Google Scholar 

  45. Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol. 2013;27:351–63.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Zhou P, Liang P, Dong B, Yu X, Han Z, Xu Y. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther. 2011;11:450–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China

    Ming-an Yu MD & Ping Liang MD

Authors
  1. Ming-an Yu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ping Liang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping Liang MD .

Editor information

Editors and Affiliations

  1. The Dept. of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China

    Ping Liang

  2. The Dept. of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China

    Xiao-ling Yu

  3. The Dept. of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China

    Jie Yu

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Yu, Ma., Liang, P. (2015). Microwave Ablation Combined with Cellular Immunotherapy for Hepatocellular Carcinoma. In: Liang, P., Yu, Xl., Yu, J. (eds) Microwave Ablation Treatment of Solid Tumors. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9315-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-9315-5_14

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-9314-8

  • Online ISBN: 978-94-017-9315-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation